Aberdeen Group
MIRM icon

Aberdeen Group’s Mirum Pharmaceuticals MIRM Stock Holding History

Aberdeen Group’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-109,758
Closed -$2.76M – 966
2024
Q1 		$2.76M Buy
+109,758
New +$3.02M 0.01% 743

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group's MIRM Position: Q2 2024 in Review

Aberdeen Group sold out of Mirum Pharmaceuticals (MIRM) in Q2 2024, closing a stake of 109,758 shares — an estimated $2.76M sold.

Aberdeen Group first reported a position in MIRM in Q1 2024 and held it in 1 quarter. The position peaked at $2.76M in Q1 2024. 160 funds tracked by Wall St. Rank hold MIRM as of Q2 2024.

  • Aberdeen Group reported no remaining Mirum Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Aberdeen Group sold 109,758 Mirum Pharmaceuticals shares in Q2 2024, an estimated $2.76M.
  • Aberdeen Group first reported a position in Mirum Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Aberdeen Group's Mirum Pharmaceuticals position peaked at $2.76M in Q1 2024.
  • 160 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2024.

Based on Aberdeen Group's 13F filing for Q2 2024, filed 9 Aug 2024.